Dexcom on Tuesday announced that its new over-the-counter continuous glucose ... While Dexcom's existing G7 CGM system is available to this population, patients have to get a prescription for ...

Recently, Dexcom won FDA approval for Stelo, which is available over the counter for people who ... That includes the company's 15-day G7 CGM, which is expected to win approval in the middle ...

With the G7, Dexcom has continued to refine the product with several improvements over the G6. The biggest of the changes is the new design, which is 60 percent smaller than its predecessor.

carry-over and spillage. The letter also noted that the company does not monitor how acetaminophen affects glucose sensing with its G7 monitors. The FDA also said Dexcom is not properly evaluating ...

Apple Watches are more than just feature-packed wearables; they're important tools for monitoring our health, including our heart rate, sleep patterns, and cardio fitness. Even if you don't know ...

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250410304660/en/ Dexcom G7 15 Day is now cleared in the ...

Months after its G7 ... Dexcom is zeroing in on the U.S. market. The diabetes device maker originally submitted the G7 system to the FDA for review at the end of 2021 but hit a regulatory ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 showing an overall mean absolute relative difference (MARD) of 8.0% ...

announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes in the United States. With an overall MARD of 8.0% ...